课题基金 / 基金详情

Mechanisms of estrogen receptor ligand signaling

Mechanisms of estrogen receptor ligand signaling
雌激素受体配体信号传导机制
批准号:
10681785
负责人:
Kendall W Nettles
金额:
$46.34万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-05-24 至 2028-04-30

项目摘要

项目成果

Kendall W Nettles的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The estrogen receptor- (ER) represents one of the most successful molecular entities as both a biomarker and target for cancer therapy, but some 30-50% of patients show de novo or acquired resistance. ER is a ligand regulated transcription factor that acts as a scaffold for histone modifying enzymes to modulate gene expression and growth of ER+ breast cancers (BCs). Importantly, the different treatment modalities of SERMs, SERDs and aromatase inhibitors induce different conformational effects on ER that often allow resistance to one type of treatment to be effectively treated by another. There is currently a significant unmet clinical need for new therapies that are effective in de novo and acquired resistance models, such as overexpression of receptor tyrosine kinases or activation of their downstream signaling pathways. We recently showed that an EGFR overexpression model rendered breast cancer cells broadly resistant to SERMs, as seen in patients. We also developed a new chemical targeting strategy for ER, which we call dual mechanism ER inhibitors (DMERI). Importantly, we identified both SERM and SERD DMERI as efficacious in the EGFR overexpression model, and many of them showed efficacy greater than fulvestrant, and in fulvestrant resistance models. The SERM DMERI may be an effective treatment for patients with EGFR overexpression at initial presentation, comprising a significant subset of ER+ BCs associated with clinical resistance. The marked difference in efficacy between SERMs and SERM DMERI in this resistant model provide us with robust chemical biology tools to dissect mechanisms of action. Our first goal is to understand the mechanisms of ER/EGFR signaling crosstalk and its regulation by different classes of ER ligands. A second goal is to understand the molecular mechanisms of ligand efficacy more generally through identifying ligand-specific coregulator- gene networks that regulate ER-dependent growth inhibition. The delineation of the ligand-receptor-coregulator gene code will enable understanding ligand mechanism of action and basic principles of transcription regulation in control of cell growth.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Tissue Selective Glucocorticoids
  • 批准号:
    10467620
  • 项目类别:
  • 资助金额:
    $55.06万
  • 财政年份:
    2022
  • 负责人:
    Kendall W Nettles
  • 依托单位:
Estrogen receptor control of inflammatory gene expression
  • 批准号:
    9515944
  • 项目类别:
  • 资助金额:
    $43.2万
  • 财政年份:
    2017
  • 负责人:
    Kendall W Nettles
  • 依托单位:
Estrogen receptor control of inflammatory gene expression
  • 批准号:
    9290487
  • 项目类别:
  • 资助金额:
    $43.2万
  • 财政年份:
    2017
  • 负责人:
    Kendall W Nettles
  • 依托单位:
Structural features of the nuclear receptor signaling code
  • 批准号:
    8345296
  • 项目类别:
  • 资助金额:
    $90.0万
  • 财政年份:
    2012
  • 负责人:
    Kendall W Nettles
  • 依托单位:
国内基金
海外基金
Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2020
  • 负责人:
    乔安娜
  • 依托单位: